F2R and neoplasm: Certain malignant cells can promote platelet activation through multiple pathways including direct activation by TF on the tumour or tumour EVs, tumour-derived thrombin generation leading to platelet activation via cleavage of platelet thrombin receptors PAR1 and PAR4, and tumour-derived cytokine and metalloprotease secretion (reviewed in [80,81]).